Parallax Volatility Advisers
OVID icon

Parallax Volatility Advisers’s Ovid Therapeutics OVID Stock Holding History

Parallax Volatility Advisers’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-756
Closed -$7K – 3654
2017
Q4 		$7K Buy
+756
New +$6.94K ﹤0.01% 3818

Other funds holding OVID

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Parallax Volatility Advisers's OVID Position: Q1 2018 in Review

Parallax Volatility Advisers sold out of Ovid Therapeutics (OVID) in Q1 2018, closing a stake of 756 shares — an estimated $7K sold.

Parallax Volatility Advisers first reported a position in OVID in Q4 2017 and held it in 1 quarter. The position peaked at $7K in Q4 2017. 48 funds tracked by Wall St. Rank hold OVID as of Q1 2018.

  • Parallax Volatility Advisers reported no remaining Ovid Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Parallax Volatility Advisers sold 756 Ovid Therapeutics shares in Q1 2018, an estimated $7K.
  • Parallax Volatility Advisers first reported a position in Ovid Therapeutics in Q4 2017 and held it in 1 quarter.
  • Parallax Volatility Advisers's Ovid Therapeutics position peaked at $7K in Q4 2017.
  • 48 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2018.

Based on Parallax Volatility Advisers's 13F filing for Q1 2018, filed 15 May 2018.